<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226769</url>
  </required_header>
  <id_info>
    <org_study_id>OCUN-023</org_study_id>
    <nct_id>NCT03226769</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease</brief_title>
  <official_title>Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and efficacy of TrueTear to standardized moist heat
      compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Actual">October 29, 2017</completion_date>
  <primary_completion_date type="Actual">October 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signs of MGD</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>Change from baseline in signs and symptoms of MGD as evaluated by SPEED questionnaire, OSDI questionnaire, MGD questionnaires, tear film breakup time, lower lid margin assessments, visual acuity and slit lamp biomicroscopy.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change from Baseline (Day 0) in corrected distance visual acuity</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>Any clinically significant changes from Baseline (Day 0) in corrected distance visual acuity will be summarized by device group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Slit lamp biomicroscopy findings</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>Any clinically significant changes from Baseline (Day 0) in slit lamp biomicroscopy findings will be summarized by device group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Device-related Adverse Events</measure>
    <time_frame>Baseline (Day 0) to Day 30</time_frame>
    <description>The proportion of participants who experience one or more device related adverse events (AEs) will be summarized for each device group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Meibomian Glands</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>TrueTear</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal application of TrueTear device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear per Patient Guide with assessments at Day 7, Day 14 and Day 30.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermalon Dry Eye Compress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions with assessments at Day 7, Day 14 and Day 30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear</intervention_name>
    <description>Intranasal application of TrueTear device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear per Patient Guide with assessments at Day 7, Day 14 and Day 30.</description>
    <arm_group_label>TrueTear</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermalon Dry Eye Compress</intervention_name>
    <description>Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions with assessments at Day 7, Day 14 and Day 30.</description>
    <arm_group_label>Thermalon Dry Eye Compress</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dry eye disease or Meibomian Gland Disease as evaluated by Standard Patient Evaluation
             for Dryness (SPEED) score, Schirmer test, Tear film breakup time and other applicable
             objective measures at the Screening and Baseline Visits

          -  Use of an artificial tear product, lid hygiene, omega-3 supplementation, antibiotics
             for the treatment of dry eye disease or Meibomian Gland Disease within one year of the
             Screening Visit

        Exclusion Criteria:

          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that may
             increase the risk of bleeding

          -  History of nasal or sinus surgery

          -  Vascularized polyp, deviated septum or severe nasal airway obstruction at the
             Screening visit

          -  Intraocular and extraocular surgery in either eye within three months of the Screening
             Visit or refractive surgery within twelve months of the Screening Visit

          -  Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic
             or active implanted electronic device in the head
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>mdlasik@comcast.net</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>For information to locate a study location near you, please visit AllerganClinicalTrials.com</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

